| 标题： | Consensus on clinical management of tumor-induced osteomalacia |
| title： | Consensus on clinical management of tumor-induced osteomalacia |
| 版本： | 原创版 |
| version： | Original |
| 分类： | 专家共识 |
| classification： | Experts consensus |
| 领域： | 诊疗 |
| field： | Diagnosis and Treatment |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | Health practitioners, endocrinologists, orthopedists, rheumatology immunologists |
| Guide users： | Health practitioners, endocrinologists, orthopedists, rheumatology immunologists |
| 证据分级方法： | We provided recommendations based on an expert review of the limited data, as well as their experiences and opinions when data was unavailable. An scientific grading system was not applicable since high quality evidence was scarce in this field. |
| Evidence grading method： | |
| 制定单位： | Chinese Society of Osteoporosis and Bone Mineral Research, Chinese Society of Endocrinology |
| Formulating unit： | Chinese Society of Osteoporosis and Bone Mineral Research, Chinese Society of Endocrinology |
| 注册时间： | 2021-01-29 |
| Registration time： | |
| 注册编号： | IPGRP-2021CN023 |
| Registration number： | |
| 指南制订的目的： | Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by excessive fibroblast growth factor 23 (FGF23) production by a tumor which often arises from a mesenchymal origin. Most clinical symptoms of TIO are the consequences of prolonged FGF23- mediated hypophosphatemia as muscle weakness, bone pain, impaired mobility and fractures. Clinical diagnosis and management of TIO is challenging, but knowledge of this condition is still restricted to a few specialized centers, leading to delay of diagnosis and appropriate treatment. The scope of the present consensus is to provide an up-to-date guidance on the assessment and treatment of TIO. |
| Purpose of the guideline： | Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by excessive fibroblast growth factor 23 (FGF23) production by a tumor which often arises from a mesenchymal origin. Most clinical symptoms of TIO are the consequences of prolonged FGF23- mediated hypophosphatemia as muscle weakness, bone pain, impaired mobility and fractures. Clinical diagnosis and management of TIO is challenging, but knowledge of this condition is still restricted to a few specialized centers, leading to delay of diagnosis and appropriate treatment. The scope of the present consensus is to provide an up-to-date guidance on the assessment and treatment of TIO. |
